免疫檢查點蛋白：各個擊破

日期: 2023-05-052024-05-16

免疫檢查點（immune checkpoint）是免疫系統(tǒng)中起抑制或激活作用的調(diào)節(jié)分子，對維持機體自身的免疫耐受、免疫應(yīng)答的時間和免疫應(yīng)激的強弱起到關(guān)鍵的調(diào)節(jié)作用。腫瘤細(xì)胞可以利用免疫檢查點通路作為免疫逃避的主要機制，特別是逃避可以識別腫瘤特異性抗原T細(xì)胞的免疫應(yīng)答。

（圖片來源：Annual Review of Immunology）

目前FDA批準(zhǔn)的幾款靶向免疫檢查點的抗體藥都是通過阻斷抑制性檢查點信號通路，達(dá)到恢復(fù)T細(xì)胞的免疫應(yīng)答，從而對腫瘤細(xì)胞起到殺傷作用。近年來，關(guān)于免疫檢查點的抗體藥物研發(fā)越來越火爆，以PD-1/PD-L1、CTLA-4為代表的抗體藥物在癌癥臨床治療上大放異彩，其中PD-1靶標(biāo)藥物在多種癌癥臨床治療中達(dá)到20%-50%的響應(yīng)率。隨著對更多免疫檢查點分子的深入研究，很多藥企也開始瞄準(zhǔn)其他免疫檢查點，試圖開辟出一條新的血路。

為了助力免疫檢查點分子相關(guān)研究，締碼生物利用HEK293人源細(xì)胞分泌表達(dá)系統(tǒng)生產(chǎn)純化出一批高質(zhì)量的免疫檢查點重組蛋白。這些在人源細(xì)胞中表達(dá)的重組蛋白具有更接近天然蛋白的二級結(jié)構(gòu)和人類細(xì)胞特有的蛋白翻譯后修飾。

部分產(chǎn)品列表

我們的長遠(yuǎn)目標(biāo)是完成所有免疫檢查點靶標(biāo)蛋白的制備和功能驗證，做到各個突破。如果您感興趣的蛋白不在列表里，歡迎私戳我們，獲得最新研發(fā)進(jìn)展！

產(chǎn)品特點

1、聚焦于表達(dá)具有功能活性的產(chǎn)品

純化重組蛋白純度驗證

Figure 1. A) Human SIRPα, hFc-His Tag on SDS-PAGE under reducing condition(PME100009). B) Human CD47, mFc-His Tag on SDS-PAGE under reducing condition(PME100008).

天然受體-配體相互作用驗證

Figure 2. ELISA plate pre-coated by 2 ug/ml (100 ul/well) Human CD47, mFc-His tagged protein (PME100008) can bind its native ligand Human SIRPα, hFc-His tagged protein (PME100009) in a linear range of 3.3-26.37 ng/ml.

治療性中和抗體結(jié)合能力驗證

Figure 3. ELISA plate pre-coated by 2 ug/ml (100 ul/well) Human CD47, mFc-His tagged protein (PME100008) can bind Anti-CD47 (Neutralizing antibody clone Hu5F9-G4)(BME100001) in a linear range of 0.061-1.606 ng/ml.

2、蛋白產(chǎn)品質(zhì)檢嚴(yán)格

締碼生物嚴(yán)格把控每一批新生產(chǎn)的重組蛋白的質(zhì)量穩(wěn)定性。

多次凍融后天然受體-配體結(jié)合能力檢測

Figure 4. Human SIRPα, hFc-His tagged protein without freeze-thaw treatment. B: Human SIRPα, hFc-His tagged protein after one freeze-thaw cycle. C: Human SIRPα, hFc-His tagged protein after three freeze-thaw cycles. D: Human SIRPα, hFc-His tagged protein after five freeze-thaw cycles.

多次凍融后蛋白完整性檢測

Figure 5. Lane 1: Human SIRPα, hFc-His tagged protein without freeze-thaw treatment, Lane 2: Human SIRPα, hFc-His tagged protein after one freeze-thaw cycle, Lane 3: Human SIRPα, hFc-His tagged protein after three freeze-thaw cycles, Lane 4: Human SIRPα, hFc-His tagged protein after five freeze-thaw cycles.

3、好禮贈送締碼生物提供研究用重組Biosimilar抗體，您無需花費高昂的價格購買臨床抗體藥物即可展開藥物的生物學(xué)效應(yīng)研究。我們的Biosimilar抗體經(jīng)過活性驗證，能夠很好的結(jié)合對應(yīng)的靶標(biāo)蛋白。

研究用Cobolimab和TIM3重組表達(dá)蛋白（PME100030）結(jié)合驗證

Figure 6. ELISA plate pre-coated by 2 ug/ml (100 ul/well) Human TIM3, mFc-His tagged protein (PME100030) can bind Anti-TIM3 Neutralizing antibody (Cobolimab)(BME100008) in a linear range of 0.24-7.81 ng/ml.研究用Biosimilar重組表達(dá)抗體產(chǎn)品列表:

Therapeutic Antibody	Antibody Specificity	DIMA catalog#
Magrolimab	Anti-CD47 mAb	BME100001
Elotuzumab	Anti-CS1 mAb	BME100002
Talacotuzumab	Anti-CD123 mAb	BME100003
Daratumumab	Anti-CD38 mAb	BME100004
Vorsetuzumab	Anti-CD70 mAb	BME100005
Pembrolizumab	Anti-PD-1 mAb	BME100006
Siltuximab	Anti-IL6 mAb	BME100007
Cobolimab	Anti-TIM-3 mAb	BME100008